Student Death Raises Plasma Safety Questions

The death of 22-year-old international student Rodiyat Alabede after donating plasma in Winnipeg has renewed questions in Canada about the safety of paid plasma collection centres, donor screening, staff training and how serious incidents are investigated.

Alabede died on October 25, 2025, after donating plasma at a centre operated by Grifols, a Spanish company involved in plasma-derived products and paid plasma collection. Health Canada and Grifols have previously said they do not believe there is a proven link between the donation process and her death, while her family and advocates say key questions about what happened inside the clinic remain unanswered.

According to Canadian media reports, an autopsy found that Alabede died of sudden cardiac arrest related to an enlarged heart, a condition she may not have known about. Her family, represented publicly by blood safety advocate Kat Lanteigne, is asking for investigative records to be released and has pointed to discrepancies in some details, including the amount of plasma collected compared with what appeared in the autopsy report.

For the family and advocates, the issue is not only whether plasma donation directly caused the death. It is also whether donor screening, staff response to alarms, training, documentation and emergency procedures were strong enough to protect donors, especially young people, students and people who may be drawn to paid donation because of financial pressure.

Previous reporting has identified two deaths after plasma donation at Grifols-run centres in Winnipeg, prompting Health Canada investigations and additional restrictions or conditions on some company operations, although no confirmed causal link has been publicly established. Inspections have also raised concerns in some centres related to donor suitability assessments, equipment maintenance, record-keeping and investigation of errors or accidents.

Health Canada says plasma-derived products are essential for treating serious and life-threatening conditions, and Canadian Blood Services explains that plasma is used both directly in hospitals and to make important medicines such as immunoglobulins, which thousands of patients in Canada rely on.

The central question is difficult but necessary: how can Canada increase plasma supply for patients without making donors the weak point in the system? Plasma donation is generally considered safe for eligible donors, but serious adverse events require strong screening, transparent reporting and public confidence that donor safety is treated as seriously as the safety of the final medical product.

For women, international students and newcomers, the story carries added weight. Many newcomers may not fully understand Canada’s health and regulatory systems, and some may not have family support nearby if a medical emergency occurs. That makes clear information before donation essential: who is eligible, what symptoms must be reported, when a donation should stop and what happens if something goes wrong.

This is not a call to frighten people away from plasma donation. Plasma saves lives. But the death of Rodiyat Alabede shows why Canada needs a careful balance between encouraging donation and protecting donors, expanding supply and strengthening oversight, and treating every serious incident with the transparency families deserve.